Research and Biotechnology Division, St. Luke's Medical Center, Quezon City, Philippines.
J Med Virol. 2014 Feb;86(2):209-16. doi: 10.1002/jmv.23717. Epub 2013 Sep 5.
Point mutations and multiple variants across the "a" determinant can destroy the antigenicity and immunogenicity of hepatitis B virus (HBV) leading to false negative assay and vaccine escape. In this study, the presence of surface gene variants of HBV was investigated among patients clinically diagnosed with chronic hepatitis B and positive for HBV DNA from 2002 to 2009. Sequence analysis of the surface gene of HBV showed that 23 (43%) of the 53 isolates had variations. Out of the 23 isolates, 15 (65%) exhibited single or multiple substitutions, which resulted to specific amino acid changes. The remaining 8 (35%) isolates had silent mutations. The amino acid substitution M133T which was associated with failure of HBsAg detection was found in one isolate (7%, 1/15), while the amino acid substitution D144A which was associated with vaccine escape was observed in one isolate (7%, 1/15). No G145R mutation was observed. Of the 15 isolates with identified single or multiple substitutions, 6 (40%) were found to have unique sequences which caused changes in the hydrophobicity profile in the protein. Unique sequence variants at amino acid positions M103I, L109P, S117R, F134I, and S136L found in this study have not yet been reported. These data should be taken into account when developing next generation HBV assays to detect both common and unique variants, and when new HBV vaccines will be designed.
点突变和“a”决定簇的多个变体可破坏乙型肝炎病毒(HBV)的抗原性和免疫原性,导致检测出现假阴性和疫苗逃逸。本研究调查了 2002 年至 2009 年间临床诊断为慢性乙型肝炎且 HBV DNA 阳性的患者中 HBV 表面基因变异体的存在情况。HBV 表面基因的序列分析显示,53 个分离株中有 23 个(43%)存在变异。在 23 个分离株中,有 15 个(65%)表现出单个或多个取代,导致特定氨基酸发生变化。其余 8 个(35%)分离株存在沉默突变。与 HBsAg 检测失败相关的氨基酸替代 M133T 存在于 1 个分离株(7%,1/15)中,而与疫苗逃逸相关的氨基酸替代 D144A 存在于 1 个分离株(7%,1/15)中。未观察到 G145R 突变。在确定存在单个或多个取代的 15 个分离株中,有 6 个(40%)具有独特序列,导致蛋白的疏水性特征发生改变。本研究发现的氨基酸位置 M103I、L109P、S117R、F134I 和 S136L 的独特序列变异尚未见报道。在开发用于检测常见和独特变异体的下一代 HBV 检测方法以及设计新的 HBV 疫苗时,应考虑到这些数据。